Extended rituximab therapy in Waldenström's macroglobulinemia

Annals of Oncology

Volumn 16, Issue 1, 2005, Pages 132-138

  Treon, Steven P ^a   Emmanouilides, C ^b   Kimby, E ^c   Kelliher, A ^d   Preffer, F ^d   Branagan, A R ^a   Anderson, K C ^a   Frankel, S R ^e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UCLA MEDICAL CENTER   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

Author keywords

CD46; CD55; CD59; Lymphoplasmacytic lymphoma; Rituximab; Waldenstr m's macroglobulinemia

Indexed keywords

CD59 ANTIGEN; COMPLEMENT; DECAY ACCELERATING FACTOR; FLUDARABINE; IMMUNOGLOBULIN M; MEMBRANE COFACTOR PROTEIN; RITUXIMAB; STEROID;

ADULT; AGED; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTHROPATHY; ARTICLE; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG TOLERABILITY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; STANDARD; STATISTICAL ANALYSIS; TUMOR CELL; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD46; ANTIGENS, CD55; ANTIGENS, CD59; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN M; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA;

EID: 12344282900     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi022     Document Type: Article

References (26)

1. Owen RG, Treon SP, Al-Katib A et al. Clinicopathological definition of Waldenström's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenström's macroglobulinemia. Semin Oncol 2003; 30: 110-115.
2. Harris NL, Jaffe ES, Stein H. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
3. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849.
4. Gertz M, Anagnostopoulos A, Anderson KC et al. Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30: 121-126.
5. Treon SP, Kelliher A, Keele B et al. Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: Therapeutic applications and considerations. Semin Oncol 2003; 30: 248-252.
6. Treon SP, Shima Y, Preffer FI et al. Treatment of plasma cell dyscrasias by antibody immunotherapy. Semin Oncol 1999; 26: 97-106.
7. Byrd JC, White CA, Link B et al. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol 1999; 10: 1525-1527.
8. Treon SP, Agus DB, Link B et al. CD20 directed serotherapy induces responses and facilitates hematological recovery in patients with Waldenstrom's macroglobulinemia. J Immunother 2001; 24: 272-279.
9. Weber DM, Gavino M, Huh Y et al. Phenotypic and clinical evidence supports rituximab for Waldenstrom's macroglobulinemia. Blood 1999; 94: 125a (Abstr).
10. Foran JM, Rohatiner AZ, Cunningham D et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18: 317-324.
11. Gertz MA, Rue M, Blood E et al. Rituximab for Waldenstrom's macroglobulinemia (E3A98): An ECOG phase II pilot study for untreated or previously treated patients. Blood 2003; 102: 148a (Abstr).
12. Treon SP, Belch AR, Kelliher A et al. CD20-directed serotherapy in multiple myeloma: Biological considerations and therapeutic applications. J Immunother 2002; 25: 72-81.
13. Dimopoulos MA, Zervas C, Zomas A et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 2002; 20: 2327-2333.
14. Golay J, Zaffaroni L, Vaccari T et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900-3908.
15. Treon SP, Mitsiades C, Mitsiades N et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in B-cell malignancies. J Immunother 2001; 24: 263-271.
16. Golay J, Lazzari M, Facchinetti V et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001; 98: 3383-3389.
17. Di Gaetano N, Xiao Y, Erba E et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001; 114: 800-809.
18. Nagajothi N, Matsui WH, Mukhina GL et al. Disruption of glycosyl-phosphatidylinositol anchored proteins enhances the complement dependent cytotoxicity of rituximab. Blood 2002; 100: 157a.
19. Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and non-malignant plasma cell disorders. Semin Oncol 2000; 27: 79-85.
20. Treon SP, Raje N, Anderson KC. Immunotherapeutic strategies for the treatment of plasma cell malignancies. Semin Oncol 2000; 27: 598-613.
21. Weber DM, Dimopoulos MA, Delasalle K et al. Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30: 243-247.
22. Treon SP, Wasi P, Emmanouilides CA et al. Combination therapy with rituximab and fludarabine is highly active in Waldenstrom's macroglobulinemia. Blood 2002; 100: 211a.
23. Treon SP, Branagan A, Anderson KC Paradoxical increases in serum IgM levels and serum viscosity following rituximab therapy in patients with Waldenstrom's macroglobulinemia. Ann Oncol 2004; 15: 1481-1483.
24. Weng WK, Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 2001; 98: 1352-1357.
25. Bannerji R, Kitada S, Flinn IW et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: Relationship to in vivo rituximab resistance. J Clin Oncol 2003; 21: 1466-1471.
26. Finberg RW, White W, Nicholson-Weller A. Decay accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. J Immunol 1992; 149: 2055.